Davis HL - Search Results

1

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

Choi AH, McNeal MM, Flint JA, Basu M, Lycke NY, Clements JD, Bean JA, Davis HL, McCluskie MJ, VanCott JL, Ward RL. Choi AH, et al. Among authors: davis hl. Vaccine. 2002 Mar 15;20(13-14):1733-40. doi: 10.1016/s0264-410x(02)00043-9. Vaccine. 2002. PMID: 11906760

2

CpG DNA as mucosal adjuvant.

McCluskie MJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Vaccine. 1999 Sep;18(3-4):231-7. doi: 10.1016/s0264-410x(99)00194-2. Vaccine. 1999. PMID: 10506647

3

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants.

McCluskie MJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Vaccine. 2000 Oct 15;19(4-5):413-22. doi: 10.1016/s0264-410x(00)00208-5. Vaccine. 2000. PMID: 11027803

4

CpG DNA is an effective oral adjuvant to protein antigens in mice.

McCluskie MJ, Weeratna RD, Krieg AM, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Vaccine. 2000 Nov 22;19(7-8):950-7. doi: 10.1016/s0264-410x(00)00215-2. Vaccine. 2000. PMID: 11115721

5

The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.

McCluskie MJ, Weeratna RD, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Vaccine. 2001 Mar 21;19(17-19):2657-60. doi: 10.1016/s0264-410x(00)00496-5. Vaccine. 2001. PMID: 11257405

6

Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.

McCluskie MJ, Weeratna RD, Clements JD, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Vaccine. 2001 Jun 14;19(27):3759-68. doi: 10.1016/s0264-410x(01)00088-3. Vaccine. 2001. PMID: 11395211

7

Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA.

McCluskie MJ, Weeratna RD, Payette PJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. FEMS Immunol Med Microbiol. 2002 Feb 18;32(3):179-85. doi: 10.1111/j.1574-695X.2002.tb00551.x. FEMS Immunol Med Microbiol. 2002. PMID: 11934561 Free article.

8

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. Weeratna RD, et al. Among authors: davis hl. Vaccine. 2005 Nov 1;23(45):5263-70. doi: 10.1016/j.vaccine.2005.06.024. Epub 2005 Jul 18. Vaccine. 2005. PMID: 16081189

9

CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.

McCluskie MJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. J Immunol. 1998 Nov 1;161(9):4463-6. J Immunol. 1998. PMID: 9794366

10

Mucosal immunization with DNA vaccines.

McCluskie MJ, Davis HL. McCluskie MJ, et al. Among authors: davis hl. Microbes Infect. 1999 Jul;1(9):685-98. doi: 10.1016/s1286-4579(99)80070-7. Microbes Infect. 1999. PMID: 10611746 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters